Discovery of indoline derivatives that inhibit esophageal squamous cell carcinoma growth by Noxa mediated apoptosis

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Molecular Pharmacology

Background:

• Antiproliferative agents are crucial for cancer treatment.
• Esophageal cancer remains a significant global health challenge.
• Novel therapeutic strategies targeting cancer cell apoptosis are needed.

Purpose of the Study:

• To synthesize and evaluate novel indoline derivatives for antiproliferative activity.
• To identify specific cancer cell lines sensitive to these derivatives.
• To elucidate the mechanism of action for potent compounds in esophageal cancer.

Main Methods:

• Synthesis of novel indoline derivatives.
• In vitro antiproliferative assays against Hela, A549, HepG2, and KYSE30 cell lines.
• In vitro and in vivo studies on esophageal squamous cell carcinoma (ESCC) cells, including cell cycle analysis and apoptosis assays.

Main Results:

• Compound 20 demonstrated potent antiproliferative activity, particularly against esophageal cancer cells (Kyse30, Kyse450, Kyse510, EC109).
• Compound 20 inhibited ESCC cell growth in vitro and in vivo.
• Mechanism studies revealed cell cycle arrest at M phase and induction of Noxa-dependent apoptosis.

Conclusions:

• Compound 20 is a novel Noxa-mediated apoptosis inducer.
• Compound 20 exhibits significant potential as an anticancer agent for esophageal cancer.
• Further clinical development of compound 20 is warranted.